These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23513360)

  • 1. When 7 isn't 7: glycohemoglobin and chronic kidney disease.
    Oppenheimer M; Jensen R; Huntington MK
    S D Med; 2013 Feb; 66(2):59-61. PubMed ID: 23513360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?
    Haneda M; Morikawa A
    Nephrol Dial Transplant; 2009 Feb; 24(2):338-41. PubMed ID: 19015168
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationship between the accuracy of glycemic markers and the chronic kidney disease stage in patients with type 2 diabetes mellitus.
    Harada K; Sumida K; Yamaguchi Y; Akai Y
    Clin Nephrol; 2014 Aug; 82(2):107-14. PubMed ID: 24985951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic Kidney Disease: Is There a Role for Glycemic Variability?
    Subramanian S; Hirsch IB
    Curr Diab Rep; 2018 Feb; 18(3):13. PubMed ID: 29450720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease.
    Okada T; Nakao T; Matsumoto H; Nagaoka Y; Tomaru R; Iwasawa H; Wada T
    Intern Med; 2011; 50(1):23-9. PubMed ID: 21212569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of serum glycated albumin and high sensitivity C - reactive protein in the insight of cardiovascular complications in diabetic chronic kidney disease patients.
    Vijayaraghavan B; Padmanabhan G; Ramanathan K
    Afr Health Sci; 2020 Mar; 20(1):308-313. PubMed ID: 33402919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycated albumin in diabetic patients with chronic kidney disease.
    Zheng CM; Ma WY; Wu CC; Lu KC
    Clin Chim Acta; 2012 Oct; 413(19-20):1555-61. PubMed ID: 22579765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring.
    Vos FE; Schollum JB; Coulter CV; Manning PJ; Duffull SB; Walker RJ
    Nephrology (Carlton); 2012 Feb; 17(2):182-8. PubMed ID: 21883672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical usefulness of glycated albumin in patients with diabetes and chronic kidney disease: Progress and challenges.
    Gan T; Liao B; Xu G
    J Diabetes Complications; 2018 Sep; 32(9):876-884. PubMed ID: 30049445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of HbA
    Lee MY; Huang JC; Chen SC; Chiou HC; Wu PY
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30567403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycated albumin versus glycated hemoglobin as glycemic indicator in hemodialysis patients with diabetes mellitus: variables that influence.
    Sany D; Elshahawy Y; Anwar W
    Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):260-73. PubMed ID: 23538348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycemic control predicts diabetic extrarenal microvascular complications but not renal survival in patients with moderate to severe chronic kidney disease.
    Crook ED; Patel S
    Ethn Dis; 2006; 16(4):865-71. PubMed ID: 17061739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.
    Okuno S; Ishimura E; Tsuboniwa N; Norimine K; Yamakawa K; Yamakawa T; Shoji S; Mori K; Nishizawa Y; Inaba M
    Osteoporos Int; 2013 Feb; 24(2):605-12. PubMed ID: 22581293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of hemoglobin A1C in the management of diabetes in dialysis patients].
    Mácsai E; Rakk E; Miléder M; Fulcz A
    Orv Hetil; 2014 Sep; 155(36):1421-5. PubMed ID: 25176516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment.
    Konya J; Ng JM; Cox H; Cooke M; Lewis N; Bhandari S; Atkin SL; Kilpatrick ES
    Diabet Med; 2013 Oct; 30(10):1250-4. PubMed ID: 23758176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of renal function on serum concentration of 1,5-anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I-III: A comparative study with HbA1c and glycated albumin.
    Hasslacher C; Kulozik F
    J Diabetes; 2016 Sep; 8(5):712-9. PubMed ID: 26615054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a U-shaped curve of A1c versus mortality?
    Bloomgarden ZT; Drexler A
    J Diabetes; 2012 Jun; 4(2):107-8. PubMed ID: 22443259
    [No Abstract]   [Full Text] [Related]  

  • 18. An interview with the authors of "Is there a U-shaped curve of A1c vs. mortality?".
    Bloomgarden Z; Drexler A
    J Diabetes; 2012 Jun; 4(2):109. PubMed ID: 22583822
    [No Abstract]   [Full Text] [Related]  

  • 19. Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4.
    Chen HS; Wu TE; Lin HD; Jap TS; Hsiao LC; Lee SH; Lin SH
    Am J Kidney Dis; 2010 May; 55(5):867-74. PubMed ID: 20202728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
    Chertow GM; Appel GB; Block GA; Chin MP; Coyne DW; Goldsberry A; Kalantar-Zadeh K; Meyer CJ; Molitch ME; Pergola PE; Raskin P; Silva AL; Spinowitz B; Sprague SM; Rossing P
    J Diabetes Complications; 2018 Dec; 32(12):1113-1117. PubMed ID: 30318163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.